The study explores the role of dietary pyruvate in combating obesity and its associated metabolic disorders. It identifies cytosolic phospholipase A2 (cPLA2) as a novel molecular target of pyruvate, demonstrating that pyruvate administration can inhibit adipogenesis and prevent high-fat diet (HFD)-induced weight gain, white adipose tissue inflammation, and metabolic dysregulation in mice. The findings suggest that pyruvate can serve as a potential therapeutic option for obesity, leveraging its anti-inflammatory properties and established safety profile.

More than 6 million children in America have been diagnosed with attention deficit hyperactivity disorder (ADHD). Now, a new study co-led by the University of Missouri has uncovered a striking correlation: Unmedicated youth with ADHD not only have significantly higher rates of obesity, but they also tend to exceed screen time recommendations and fall short of meeting crucial sleep guidelines.

This study investigates the proteomic landscape of ferroptosis, a type of cell death characterized by lipid peroxidation and iron dependency. Through proteomic analysis, the researchers identified choline/ethanolamine phosphotransferase 1 (CEPT1) as an interacting partner of lysophosphatidylcholine acyltransferase 3 (LPCAT3), crucial for maintaining LPCAT3 protein stability. Contrary to its known role in phospholipid synthesis, CEPT1 was found to suppress ferroptosis by interacting with phospholipases and breaking down pro-ferroptotic polyunsaturated fatty acid (PUFA)-containing phospholipids. This discovery highlights a novel function of CEPT1 in the regulation of ferroptosis.

A research group led by Associate Professor Ayako Okado-Matsumoto from the Department of Biology at Toho University, in collaboration with Professor Ryuji Sakakibara (at the time of the study) from the Department of Neurology at Toho University Medical Center Sakura Hospital, discovered that the formation of mitochondrial respiratory chain supercomplexes, encompassing energy production-related enzymes, in the peripheral blood leukocytes of patients with neurodegenerative diseases (such as Alzheimer's disease, Parkinson's disease, and dementia with Lewy bodies) correlates with disease progression.